Background: The objective of this study was to report the results of a series of 12 patients with papillary carcinoma aged 16 years or younger, who were prepared with recombinant human TSH (rhTSH) for remnant ablation with 131I. The TSH levels achieved and the safety of 24 cycles of rhTSH administration (ablation and control assessment) are reported. Methods: All patients were prepared using the same protocol as recommended for adults. Eight to 12 months after initial therapy, the patients were submitted to neck ultrasound, measurement of stimulated Tg and anti-Tg antibodies (TgAb), and diagnostic whole-body scanning (DxWBS). Results: TSH levels >50 mIU/l were achieved in all patients. An adverse reaction (mild nausea and headache) was observed in 1/24 cycles (4.1%). Eight (88.8%) of 9 patients with uptake in the thyroid bed in post-therapy whole-body scanning (RxWBS) achieved complete remission. One patient presented TgAb in the absence of apparent disease. In addition, imaging methods showed no apparent disease in the 2 patients with lymph node metastases in RxWBS. Elevated Tg persisted in 1 patient with pulmonary micrometastases. Conclusion: The present results demonstrate the efficacy and safety of rhTSH in children and adolescents.

Keywords:
Thyroid ablation, Recombinant human TSH, Children, Thyroid cancer
1.
Rosario PW, Malard Xavier AC: Recombinant human TSH (rhTSH) in thyroid remnant ablation with 1.1 GBq 131-iodine in low risk patients. Am J Clin Oncol DOI: 10.1097/COC.0b013e318201a41a (E-pub ahead of print).
2.
Rosario PW, Malard Xavier AC, Calsolari MR: Recombinant human TSH (rhTSH) in thyroid remnant ablation with 131-iodine in high risk patients. Thyroid 2010;20:1247-1252.
3.
Rosario PW, Borges MA, Purisch S: Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. J Nucl Med 2008;49:1776-1782.
4.
Jarzab B, Handkiewicz-Junak D, Wloch J: Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review. Endocr Relat Cancer 2005;12:773-803.
5.
Rosario PW, Fagundes TA, Purisch S, Padrao EL, Rezende LL, Barroso AL: Recombinant TSH in ablative therapy and follow-up of patients with differentiated thyroid carcinoma. Arq Bras Endocrinol Metabol 2005;49:350-358.
6.
Iorcansky S, Herzovich V, Qualey RR, Tuttle RM: Serum thyrotropin (TSH) levels after recombinant human TSH injections in children and teenagers with papillary thyroid cancer. J Clin Endocrinol Metab 2005;90:6553-6555.
7.
Luster M, Handkiewicz-Junak D, Grossi A, Zacharin M, Taïeb D, Cruz O, Hitzel A, Casas JA, Mäder U, Dottorini ME, Pediatric rhTSH Investigators Group: Recombinant thyrotropin use in children and adolescents with differentiated thyroid cancer: a multicenter retrospective study. J Clin Endocrinol Metab 2009;94:3948-3953.
8.
Ralli M, Cohan P, Lee K: Successful use of recombinant human thyrotropin in the therapy of pediatric well-differentiated thyroid cancer. J Endocrinol Invest 2005;28:270-273.
9.
Song H, He B, Prideaux A, Du Y, Frey E, Kasecamp W, Ladenson PW, Wahl RL, Sgouros G: Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J Nucl Med 2006;47:1985-1994.
10.
Rosario PW, Faria S, Bicalho L, Gatti Alves MF, Borges MAR, Purisch S, Padrão EL, Rezende LL, Barroso AL: Ultrasonographic differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma. J Ultrasound Med 2005;24:1385-1389.
11.
Rosario PW, Tavares Júnior WC, Biscolla RP, Purisch S, Maciel RM: Usefulness of neck ultrasonography in the follow-up of patients with differentiated thyroid cancer. Arq Bras Endocrinol Metabol 2007;51:593-600.
12.
Lau WF, Zacharin MR, Waters K, Wheeler G, Johnston V, Hicks RJ: Management of paediatric thyroid carcinoma: recent experience with recombinant human thyroid stimulating hormone in preparation for radioiodine therapy. Intern Med J 2006;36:564-570.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.